M R Middleton

Summary

Affiliation: University of Manchester
Country: UK

Publications

  1. ncbi request reprint Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
    M R Middleton
    Christie Hospital, Manchester, United Kingdom
    J Clin Oncol 18:158-66. 2000
  2. ncbi request reprint O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts
    M R Middleton
    Cancer Research Campaign Department of Carcinogenesis, Paterson Institute for Cancer Research, Manchester, UK
    Int J Cancer 85:248-52. 2000
  3. ncbi request reprint Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts
    M R Middleton
    Cancer Research Campaign Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
    Cancer Chemother Pharmacol 45:15-20. 2000
  4. ncbi request reprint O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study
    M R Middleton
    Cancer Research Campaign Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
    Int J Cancer 88:469-73. 2000
  5. pmc A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
    M R Middleton
    CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
    Br J Cancer 82:1158-62. 2000
  6. ncbi request reprint Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma
    S Danson
    Christie Hospital, Manchester, United Kingdom
    J Clin Oncol 21:2551-7. 2003
  7. pmc O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma
    M R Middleton
    Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
    Br J Cancer 78:1199-202. 1998
  8. pmc O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib
    A J Watson
    Cancer Research UK Carcinogenesis Group, Paterson Institute for Cancer Research, Manchester, UK
    Br J Cancer 100:1250-6. 2009
  9. ncbi request reprint Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma
    S C White
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, United Kingdom
    Cancer 92:601-8. 2001
  10. ncbi request reprint Temozolomide: a novel oral alkylating agent
    S J Danson
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 9BX, UK
    Expert Rev Anticancer Ther 1:13-9. 2001

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
    M R Middleton
    Christie Hospital, Manchester, United Kingdom
    J Clin Oncol 18:158-66. 2000
    ....
  2. ncbi request reprint O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts
    M R Middleton
    Cancer Research Campaign Department of Carcinogenesis, Paterson Institute for Cancer Research, Manchester, UK
    Int J Cancer 85:248-52. 2000
    ..2/9 deaths; 6.84% weight loss vs. 9.48%, p = 0.019). 4BTG is a potent inactivator of ATase and enhances the therapeutic ratio of temozolomide in this model system to a greater extent than O(6)-BG...
  3. ncbi request reprint Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts
    M R Middleton
    Cancer Research Campaign Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
    Cancer Chemother Pharmacol 45:15-20. 2000
    ....
  4. ncbi request reprint O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study
    M R Middleton
    Cancer Research Campaign Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
    Int J Cancer 88:469-73. 2000
    ..Myelosuppression precludes its wider application, but MGMT in PBMCs predicted the dose intensity of temozolomide that patients could sustain, suggesting a means by which individuals suitable for this approach might be identified...
  5. pmc A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
    M R Middleton
    CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
    Br J Cancer 82:1158-62. 2000
    ..75 days/treatment cycle vs 2.29 with dacarbazine and interferon). DBCT combination therapy cannot be recommended as standard treatment for advanced melanoma. Dacarbazine remains the standard chemotherapy for this condition...
  6. ncbi request reprint Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma
    S Danson
    Christie Hospital, Manchester, United Kingdom
    J Clin Oncol 21:2551-7. 2003
    ..The objectives of this randomized phase II, two-center study were to determine response rates, overall survival, and tolerability of the regimens in patients with advanced metastatic melanoma...
  7. pmc O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma
    M R Middleton
    Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
    Br J Cancer 78:1199-202. 1998
    ..3. Thus, measurements of pretreatment levels of MGMT in melanoma did not predict for response to temozolomide...
  8. pmc O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib
    A J Watson
    Cancer Research UK Carcinogenesis Group, Paterson Institute for Cancer Research, Manchester, UK
    Br J Cancer 100:1250-6. 2009
    ..Early recovery of MGMT activity in tumours suggested that more protracted dosing with LM is required. Extended dosing of LM completely inactivated PBMC MGMT, and resulted in persistent levels of O(6)-meG in PBMC DNA during treatment...
  9. ncbi request reprint Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma
    S C White
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, United Kingdom
    Cancer 92:601-8. 2001
    ..The lower risk of life-threatening sepsis and less need for hospitalization or intravenous antibiotic courses is advantageous in this susceptible patient population...
  10. ncbi request reprint Temozolomide: a novel oral alkylating agent
    S J Danson
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 9BX, UK
    Expert Rev Anticancer Ther 1:13-9. 2001
    ..Studies of new drug schedules and of drugs to ameliorate temozolomide resistance offer the prospect of increased efficacy...
  11. ncbi request reprint Effect of temozolomide on central nervous system relapse in patients with advanced melanoma
    M J Paul
    Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
    Melanoma Res 12:175-8. 2002
    ..03). These results support the investigation of temozolomide as a replacement for DTIC in systemic treatment regimens for melanoma...
  12. ncbi request reprint Inhibition of O6-methylguanine DNA methyltransferase (MGMT) in solid tumors by lomeguatrib
    A Sabharwal
    Oxford Radcliffe Hospitals, Oxford, United Kingdom Paterson Institute, Manchester, United Kingdom University of Newcastle, Newcastle, United Kingdom Cancer Research U K, London, United Kingdom
    J Clin Oncol 26:3597. 2008
    ..De novo synthesis is required to restore cellular MGMT levels. We determined the dose of LM needed reliably to deplete MGMT in 3 tumor types, to inform future combination studies with methylating agents...
  13. pmc Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
    J Cummings
    Clinical and Experimental Pharmacology Group, Manchester Cancer Research Centre, Paterson Institute for Cancer Research, University of Manchester, Manchester M20 4BX, UK
    Br J Cancer 106:1766-71. 2012
    ..Preclinical studies demonstrated early drug-induced apoptosis in tumour endothelial cells at 1-3 h and secondary tumour cell necrosis between 6 and 72 h...